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Abstract
Critical illness polyneuropathy (CIP) and myopathy (CIM) are major
complications of severe critical illness and its management. CIP/
CIM prolongs weaning from mechanical ventilation and physical
rehabilitation since both limb and respiratory muscles can be
affected. Among many risk factors implicated, sepsis, systemic
inflammatory response syndrome, and multiple organ failure appear
to play a crucial role in CIP/CIM. This review focuses on epidemiol-
ogy, diagnostic challenges, the current understanding of patho-
physiology, risk factors, important clinical consequences, and
potential interventions to reduce the incidence of CIP/CIM.
CIP/CIM is associated with increased hospital and intensive care
unit (ICU) stays and increased mortality rates. Recently, it was
shown in a single centre that intensive insulin therapy significantly
reduced the electrophysiological incidence of CIP/CIM and the
need for prolonged mechanical ventilation in patients in a medical
or surgical ICU for at least 1 week. The electrophysiological
diagnosis was limited by the fact that muscle membrane
inexcitability was not detected. These results have yet to be
confirmed in a larger patient population. One of the main risks of
this therapy is hypoglycemia. Also, conflicting evidence concerning
the neuromuscular effects of corticosteroids exists. A systematic
review of the available literature on the optimal approach for
preventing CIP/CIM seems warranted.
Introduction
Critical illness polyneuropathy (CIP), first described by Bolton
and colleagues in 1986 [1], is a frequent complication of
critical illness, acutely and primarily affecting the motor and
sensory axons. This disorder can cause severe limb
weakness and prolonged weaning. Several reports of
severely ill patients with muscle wasting and polyneuropathy
already existed by the end of the 19th century. Improvement
of diagnostics later on revealed that muscle may be primarily
involved, which is called myopathy in critical illness or critical
illness myopathy (CIM) [2-5]. The condition has also been
described in children [6].
Clinical signs and diagnosis
CIP and CIM share the major clinical sign of flaccid and
usually symmetrical weakness. Other clinical signs include
the reduction in or absence of deep tendon reflexes [7-9].
Patients with CIP may show a distal loss of sensitivity to pain,
temperature, and vibration. Although facial muscles are relatively
spared, they can be involved and ophthalmoplegia may occur,
although it is very rare [1,7,9]. Weaning problems are
ascribed to the involvement of the phrenic nerves and the
diaphragm, and intercostal and other accessory respiratory
muscles can be affected as well [1,10]. It should be noted that
CIP represents the response of the peripheral nervous system
to critical illness, but the central nervous system also is
frequently affected by critical illness, manifesting as a diffuse
encephalopathy that occurs very early in the process [11].
Currently, several investigators use the Medical Research
Council (MRC) sum score as a screening tool for CIP/CIM
[12]. This score evaluates muscle force on a scale from 0 to
5 in three muscle groups of both upper and lower limbs,
rendering a maximum score of 60. CIP/CIM is arbitrarily
diagnosed if the MRC sum score is less than 48 [12].
Though originally developed for and validated in patients with
Guillain-Barré syndrome [13], this score is very interesting as
it reflects actual limb muscle force. However, a limitation of
this score is that it reflects only weakness, without pointing
out its cause. Also, patients need to be cooperative. There-
fore, the MRC sum score can be used only after awakening
(for example, at the onset of weaning from mechanical
ventilation). As for any voluntary manoeuvre in the intensive
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care unit (ICU), satisfactory patient comprehension and
cooperation should be evaluated and confirmed. Otherwise,
overestimation of muscle weakness may occur [14].
Technical investigations can provide further evidence for
CIP/CIM. These include serum measurements of muscle
necrosis parameters (serum creatine kinase, CK), electro-
myography (EMG) and nerve conduction studies, and muscle
biopsy. Serum CK levels are not very helpful since they are
normal if muscle necrosis is absent or scattered, which
commonly is the case. Even in patients with overt muscle
necrosis, an increase in CK is often transient and can be
missed. EMG and nerve conduction studies provide a
bedside method to confirm the diagnosis and to exclude
other neuromuscular causes of weakness, although routine
electrophysiological examination oftentimes cannot discriminate
between CIP and CIM in critically ill, sedated, uncooperative,
or extremely weak patients [15]. In contrast to the MRC sum
score mentioned above, it can be used before patients have
recovered satisfactory consciousness and cooperation and
therefore offers the advantage of identifying affected patients
in an earlier stage. The first electrophysiological sign that can
occur very early, even within 2 to 5 days after the onset of
critical illness, is a reduction in amplitude of the nerve
conduction potentials (compound muscle action potential
(CMAP) or sensory nerve action potential (SNAP) or both)
with preserved conduction velocity. Recent data showed that
the majority of patients admitted for sepsis showed reduced
nerve conduction amplitudes within 3 days of admission and
that change of baseline nerve conduction response amplitude
at 1 week was predictive for the development of acquired
neuromuscular dysfunction [16]. The reduction in amplitudes
often precedes the clinical findings as well as the accom-
panying fibrillation potentials and positive sharp waves that
may not occur until the second or third week [17-19]. A
multicentre prospective trial showed that electrophysiological
screening using peroneal CMAP reduction below two
standard deviations of the normal value accurately identifies
patients with CIP/CIM [20]. Abnormal SNAPs are charac-
teristic for CIP, although local oedema can interfere with
optimal sensory nerve stimulation and recording. In addition,
CIP and CIM often coexist. Electrophysiological differen-
tiation between CIP and CIM is possible in the adequately
awake and cooperative patient in whom voluntary motor unit
potential recruitment can be obtained, in the rare case when
the polyneuropathy is purely sensory [21], or using direct
muscle stimulation. This shows reduced or absent action
potentials in the case of CIM, reflecting loss of muscle
electrical excitability, in contrast with normal values in CIP
[22-24]. However, this technique requires an experienced
examiner in order to obtain reliable results. As routine electro-
physiological examination in critically ill patients frequently
cannot differentiate between neuropathy and myopathy
[15,25], muscle biopsy can be performed and is considered
a gold standard for the involvement of muscles in the disease
process. Percutaneous muscle biopsy is relatively easy and
can be performed at the bedside. Determination of the
myosin/actin ratio has been suggested for rapid diagnosis of
myopathy [26]. The clinical relevance of differentiating
between neuropathy and myopathy is still under debate. A
small case series of ICU survivors suggested a better
outcome for patients with CIM in contrast with CIP [27]. A
previous larger retrospective trial did not show any difference
in outcome between CIP and CIM [28], and a recent
systematic review (though not including the data of Guarneri
and colleagues [27]) found insufficient data to confirm this
[29].
Different changes in muscle histomorphology can be
recognised. Three subtypes of acute myopathy of intensive
care have been described [30] and are often grouped
together as so-called ‘acute quadriplegic myopathy’: (a)
diffuse non-necrotising ‘cachectic’ myopathy, (b) thick-
filament myopathy or myopathy with selective loss of thick
(myosin) filaments, and (c) acute necrotising myopathy. Non-
necrotising myopathy is accompanied by abnormal variation
of muscle fibre size, fibre atrophy, predominantly type II fibres,
angulated fibres, internalised nuclei, rimmed vacuoles, fatty
degeneration of muscle fibres, and fibrosis. Type II fibre
atrophy, however, is also reported in neuropathy and disuse
atrophy. In thick-filament myopathy, a selective loss of myosin
filaments is the predominant finding. This diagnosis requires
the use of electron microscopy. Acute necrotising myopathy
of critical illness is characterised by prominent myonecrosis,
with vacuolisation and phagocytosis of muscle fibres, visible
on optical microscopy as sparse, diffuse, or massive lesions.
In a minority of the patients, this disease can progress to
frank rhabdomyolysis [14,31,32]. Although muscle biopsy
remains the diagnostic method of choice for detection of
structural abnormalities, it remains invasive and therefore is
not a practical screening tool. However, using biopsy and
direct muscle stimulation, it has been recognised that the
incidence of CIM is much higher than previously thought and
many patients might even have a combination of CIP and CIM
[15,16,33,34].
Apart from the difficulties in differentiating CIP and CIM, they
frequently co-occur. Electrophysiological and histological
examination of patients indeed showed a significant overlap
of CIP and CIM [15,17]. This has led to an often descriptive
terminology in the literature, including terms such as ‘ICU-
acquired paresis’ and ‘acquired neuromuscular disorders’.
From a clinical point of view, CIP and CIM are often treated
as a group and therefore are designated as critical illness
polyneuromyopathy, critical illness neuromyopathy, or critical
illness polyneuropathy and myopathy (CIP/CIM) [14,33,35,36].
Incidence
The incidence rates reported depend on the specific ICU sub-
population that is studied, the risk factors to which this popu-
lation was exposed, the diagnostic criteria used, and the timing
of diagnosis during the acute illness [37]. In sepsis or systemicPage 3 of 9
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inflammatory response syndrome (SIRS), 70% of patients
develop CIP [10]. When further complicated by multiple organ
failure (MOF), the incidence increases to up to 100% [18].
Importantly, critically ill comatose patients may become
completely paralysed due to CIP/CIM [15]. Similarly, about
60% of patients with acute respiratory distress syndrome
(ARDS) suffer from this disease [38]. In unselected patients
receiving mechanical ventilation for at least 4 to 7 days, the
occurrence of CIP/CIM was noticed to be 25% to 33% on
clinical evaluation [12,36,39] and up to 58% on electro-
physiological evaluation [40-42]. Of patients in the ICU for at
least 7 days, 49% to 77% [21,43,44] will acquire CIP/CIM. A
neuromuscular disorder with a predominant muscle component
(CIM) develops in at least one third of ICU patients treated for
status asthmaticus [45], 7% of patients after orthotopic liver
transplantation [46], 38% of critically ill patients [33], and 68%
of patients in the ICU for at least 7 days [21].
Short-term and long-term implications
CIP and CIM have an important impact on the outcome of
patients in the ICU. They typically cause muscle weakness
and paralysis and impair rehabilitation [42] in up to 100% of
patients staying in the ICU for at least 4 weeks [47]. CIP/CIM
itself may prolong the need for ventilatory support [39,41,43,
44,48] as the phrenic nerve and diaphragmatic muscle can
be involved [10]. Not surprisingly, the duration of weaning in
these patients is increased 2 to 7 times [10,33,39,41,49].
CIP/CIM is associated with increased ICU and hospital stays
[41,49] and elevated mortality rates [41,42,49,50], although
other data suggest that patient selection may partially explain
this [20]. Improvement occurs within weeks in mild cases and
within months in severe cases. This recovery is characterised
by progressive reinnervation of muscle and, in CIP, restora-
tion of sensory function. Full recovery has been reported in
over 50% of patients [10,29,51]. However, in the more
severe cases, recovery may be incomplete or may not even
occur at all [1,10,47]. A systematic review [29] reported
severe disability impeding independent walking or spon-
taneous ventilation in 28% of patients, although this figure
may be high due to the limited follow-up period in several
case series. A small case series suggests that undetectable
CMAPs could be a predictor of prolonged functional
disability [52]. In patients recovering from ARDS, persistent
functional limitation due to muscle wasting and weakness
1 year after discharge was noted in all patients [53]. Clinical
and neurophysiological signs may remain present for up to 5
years after ICU discharge [47]. In the most severe cases, up
to 32% are reported to remain severely disabled with tetra-
paresis, tetraplegia, or paraplegia [51]. Persistent milder
disabilities are common even in patients with complete
functional recovery, and in a small case series impaired quality
of life after 1 year was frequently present in survivors [54].
Risk factors
A large number of studies have been performed to identify
patients at risk for CIP/CIM. Among these, both prospective
and retrospective trials have repeatedly identified sepsis,
SIRS, and MOF as crucial risk factors. Also, the central role
of MOF in the pathophysiology has been confirmed in a
recent systematic review [37] and in a prospective cohort
study [20]. Data reported on a number of other factors, such
as hypoxia [55], hypotension [56], hyperpyrexia [57], and age
[38], are not always consistent. Aminoglycosides have received
particular attention as two studies associated their use with
CIP [40,42]. However, other authors could not confirm these
findings [10,12,38,43,44,49,58], and therefore it seems that
any association is not likely to be causal. The following
factors have been identified as independent risk factors in
prospective studies: female gender [12], severity of illness
[33,36], duration of organ dysfunction [12], renal failure and
renal replacement therapy [49], hyperosmolality [49], paren-
teral nutrition [49], low serum albumin [10], duration of ICU
stay [10,43], vasopressor and catecholamine support [43],
and central neurologic failure [49]. Hyperglycemia also has
been identified as an independent risk factor [10,43], with an
important potential impact in terms of prevention (see
‘Prevention and therapy’ section).
The impact of corticosteroids (CSs) on neuromuscular
function in the ICU has been the subject of controversy. Many
reports have found CIM to occur in patients treated with a
combination of CSs and neuromuscular blocking agents
(NMBAs). The myopathy that occurs in these patients mostly
treated for severe asthma, chronic obstructive pulmonary
disease, solid organ transplantation, leukemia, or lymphoma is
most commonly a thick-filament myopathy. However, four
prospective studies in unselected ICU populations could not
identify CSs as an independent risk factor for CIP [49] or
CIP/CIM [33,36,43], although three other prospective trials
on weakness did [12,46,53]. In one study, CSs were even
found to be an independent protective factor for the occur-
rence of CIP/CIM [44]. Similarly, four prospective trials did
not identify NMBAs as an independent risk factor for CIP or
CIP/CIM [12,33,36,43], but two other trials did [44,49]. As
CIM has been reported in patients receiving only one of these
agents or receiving neither, it is clear that these drugs are not
critical or essential in order to develop CIP/CIM.
Pathophysiology
The pathophysiology of CIP and CIM is complex and still
unclear. A schematic overview is shown in Figure 1 [59]. The
association between CIP/CIM and other organ failures has
raised the question as to whether neuromuscular involvement
is not simply a part of a systemic critical illness, representing
just another organ failure. Bolton and colleagues [10,60]
hypothesised that sepsis-related disturbance of the micro-
circulation in peripheral nerves and muscles is a crucial event
in the pathogenesis. In CIP, this may be mediated by the
enhanced expression of E-selectin in the vascular endo-
thelium of the peripheral nerves, induced by pro-inflammatory
cytokines [61]. Hyperglycemia also may impair the micro-
circulation to the peripheral nerve. Moreover, cytokines
Available online http://ccforum.com/content/12/6/238secreted in sepsis have histamine-like properties that may
increase microvascular permeability [60]. The resulting
endoneural oedema could induce hypoxemia and energy
depletion by increasing intercapillary distance and other
mechanisms. Severe energy deficits would result, inducing
primary axonal degeneration. Passive uptake of glucose with
increased generation and deficient scavenging of reactive
oxygen species could contribute to bioenergetic failure.
Increased permeability may also enhance the passage of
neurotoxic factors in the endoneurium and promote
endothelial cell-leucocyte adhesion and extravasation of
activated leucocytes within the endoneurial space, where
they can induce tissue injury with local cytokine production
[61]. Also, some cytokines may have direct toxic effects on
peripheral nerves. A possible role for a neurotoxic factor in
the pathogenesis of CIP has been suggested [62].
The pathophysiology of CIM is also complex, involving meta-
bolic, inflammatory, and bioenergetic alterations. Protein cata-
bolism and muscle wasting are observed in CIM. Proteolytic
pathways involving calpain [63] and the ubiquitin-proteasome
pathway [64,65] are upregulated due to pro-inflammatory
cytokines in conjunction with increased apoptosis [66]. As
calpain is a calcium-activated protease, altered cellular
calcium homeostasis due to endotoxemia and inflammation
might play a role [60,67]. Also, acute stimulation of the TGF-
β/MAPK (transforming growth factor-beta/mitogen-activated
protein kinase) pathway following stress stimuli has been
suggested to explain the muscle loss, coupled with the
activation of the ubiquitin-proteasome pathway [68]. Muscle
biopsies in these patients demonstrate a decrease in total
amino acid concentration and, most strikingly, the glutamine
levels [69]. Glutamine is known to stimulate protein synthesis
and inhibit protein breakdown. There appears to be a relative
deficiency of glutamine to increased demands in critical
illness. Decreased levels of anabolic hormones and increased
levels of catabolic hormones may contribute to myofilament
loss and apoptosis in CIM [31]. Channelopathy is another
mechanism that has been suggested in the pathophysiology.
Electrodiagnostic studies often show evidence of muscle
Critical Care    Vol 12 No 6 Hermans et al.
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Figure 1
Presumed pathophysiological mechanisms and their interactions involved in the development of critical illness polyneuropathy/critical illness
myopathy (CIP/CIM). CS, corticosteroids; NMBA, neuromuscular blocking agent; ROS, reactive oxygen species; SR, sarcoplasmatic reticulum.membrane inexcitability. This may be related to the
inactivation of sodium channels at the resting potential and a
shift in the voltage dependence of channel inactivation
[70-73]. Interaction of lipopolysaccharide with voltage-gated
sodium channels may contribute to muscle membrane
inexcitability in sepsis [74]. Also, altered expression of nitric
oxide synthetases has been suggested to possibly affect
muscle membrane excitability in CIM as nitric oxide takes part
in the maintenance of muscle fibre resting potential [75]. CIM
may include alterations in the excitation-contraction coupling
as blood sera from patients with CIM were found to affect not
only the excitability of muscle fibre membranes but also the
release of calcium from the sarcoplasmatic reticulum (SR)
[76]. Evidence for these mechanisms and a possible
‘myotoxic’ factor responsible for this comes from animal data
in which sera of patients with CIM had differential effects on
resting and action potentials, sodium channels, and the
excitation-contraction coupling process at the level of the SR-
Ca2+ release [76]. Nitric oxide overproduction, antioxidant
depletion, mitochondrial dysfunction, muscle ATP depletion,
and bioenergetic failure due to damage or inhibition of
complex I of the respiratory chain may also be important [77].
The exact role of CSs and NMBAs in CIM is not clearly
understood. Interestingly, in experimental models, muscle
changes are prevented by concomitant administration of
RU38486, a muscle CS receptor antagonist [78], suggesting
that sepsis-induced muscle changes are mediated, at least
partly, by endogenous CSs. Bolton [60] hypothesised that
increased capillary permeability due to sepsis-induced
release of cytokines allows NMBAs to cross the membrane
and have direct toxic effects on the nerve or cause functional
denervation of muscle, thereby possibly facilitating toxic
effects of CSs or inflammatory mediators.
Functional denervation resulting from nerve injury in CIP may
provide the link between CIP and CIM. Experimental CS-
induced muscle alterations are significantly enhanced by limb
denervation prior to exposure to CSs, suggesting that, in ICU
patients, the axonal component of CIP/CIM or a chemical
denervation such as induced by neuromuscular blockers
could increase muscle susceptibility to CSs [79]. Another
hypothesis is that both CIP and CIM represent different
manifestations of a single pathologic mechanism in which
sepsis triggers electrical inexcitability of the nerve, the muscle
[80], and even the heart and central nervous system [81].
Also, evidence for a role of immune mechanisms in patients
with CIP/CIM exists. Indeed, small numbers of activated
leucocytes producing pro- and anti-inflammatory cytokines
infiltrate the skeletal muscle of patients with CIP/CIM [34].
Whereas most studies have focused on limb muscles, new
data have shed light on some of the mechanisms of the
diaphramatic muscle involvement. Diaphragm immobilisation
in animal models under mechanical ventilation for only 18
hours induces a significant decrease in diaphragmatic force
coupled with muscle atrophy and an increase in muscle
markers of oxidative stress and calpain and ubiquitin-protea-
some proteolytic activity [82], enhanced by NMBAs [83], and
prevented by intermittent spontaneous breathing [84] and
antiproteases [85]. Similar functional and histochemical
diaphragmatic changes have been reported in animals sub-
mitted to experimental sepsis [86]. Preliminary human data
suggest that the combination of 18 to 69 hours of complete
diaphragmatic inactivity and mechanical ventilation results in
marked atrophy of human diaphragm myofibres. These
findings are consistent with increased diaphragmatic proteo-
lysis during inactivity [87].
Prevention and therapy
As CIP/CIM not only has immediate detrimental effects in
causing weaning difficulties but also causes long-term
problems due to prolonged rehabilitation, it is a major cause
of morbidity in patients surviving the acute phase of their
critical illness. Until recently, only preventive measures
consisting of reducing exposition to known risk factors and
supportive measures were recommended in critically ill
patients. Most authors agree on aggressive treatment of
sepsis as the most important measure to reduce the
incidence of CIP/CIM. CSs and NMBAs, if indicated, should
be used at a minimal dose for as short a period as possible.
Managing difficulty in weaning from mechanical ventilation
[88] as well as rehabilitation programs [89] and avoiding
additional pressure neuropathies by careful positioning are
also considered to be major issues.
Several specific therapies have been mentioned as theo-
retically interesting and therefore potentially beneficial to
prevent CIP/CIM. These include nutrition schemes and
nutritional interventions [1], supplement therapies [90], anti-
oxidant therapy [91], and the use of testosterone derivates
[92], growth hormone [93], and immunoglobulins [58]. None
of these, however, has actually been shown to have beneficial
effects on muscle function in ICU patients.
Recently, the effect of intensive insulin therapy on CIP/CIM
and the need for prolonged mechanical ventilation have been
studied in surgical (SICU) and medical (MICU) ICU popula-
tions. Interest in this therapy was generated by the fact that
hyperglycemia was associated with CIP/CIM by Witt and
colleagues in 1991 [10], a finding that was confirmed by
other investigators [12]. Avoiding hyperglycemia using insulin
therapy to maintain strict glycemic control therefore may be
beneficial to prevent CIP/CIM. Insulin itself has some
potential beneficial effects, including anti-inflammatory effects
[94], endothelial protection [95], improvement of dyslipemia,
and neuroprotective effects in animals [96], and is also an
anabolic hormone. Two prospectively planned subanalyses
[43,44] of two large randomised controlled trials [97,98]
were performed. The trials evaluated the effect of intensive
insulin therapy on a SICU and a MICU (aiming at glycemia of
80 to 110 mg/dL) versus conventional insulin therapy in
which insulin was started when glycemia rose above
Available online http://ccforum.com/content/12/6/238
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180 mg/dL. In the subanalyses, intensive insulin therapy
significantly reduced the incidence of CIP/CIM detected on
systematic electrophysiological investigation in patients in the
ICU for at least 1 week, from 49% to 25% in the SICU
(P <0.0001) and from 51% to 39% in the MICU (P = 0.02).
Also, the need for prolonged mechanical ventilation, defined
as mechanical ventilation for at least 2 weeks, was reduced
from 42% to 32% in the SICU (P = 0.04) and from 47% to
35% in the MICU (P = 0.01). Multivariate analysis attributed
the beneficial effect on CIP/CIM to glycemic control [43],
whereas the beneficial effect on prolonged mechanical
ventilation was due to the insulin dose and was not
completely explained by the benefit on CIP/CIM [44].
Although a beneficial effect of intensive insulin therapy is
present in patients in whom tight glucose control did not
totally succeed in lowering glycemic levels to the preset goal
(but rather to between 110 and 150 mg/dL), the benefit on
CIP/CIM as well as on mortality is most pronounced in the
patients with the tightest control (80 to 110 mg/dL) [99].
These results are derived from post hoc analysis and need to
be confirmed. As the beneficial effects of intensive insulin
therapy on ICU patients are currently derived from a single
centre, these results await confirmation in a larger population.
The methodology of electrophysiological diagnosis was
limited by the fact that muscle membrane inexcitability was
not detected. Further investigations are needed to evaluate
the extent to which the significant benefits in terms of
electrophysiological abnormalities in the form of spontaneous
electrical activity translate into clinical benefits in terms of
muscle strength and recovery of neuromuscular function at
and after discharge from the ICU [100].
Finally, although the use of CSs is currently discouraged, they
theoretically could be interesting as, first of all, survival benefit
is present in some subgroups of ICU patients treated with
CSs such as those with septic shock, ARDS, and acute
asthma. Moreover, CSs in specific ICU settings may reduce
the duration and severity of MOF, which is the crucial risk
factor for CIP/CIM [101]. CSs indeed showed a preventive
effect on CIP/CIM in one prospective trial [44], and in a
second prospective trial a trend toward beneficial effect was
noticed [43]. The three prospective trials that identified CSs
as independent risk factors for acquired weakness in the ICU
either did not report glycemia [51] or did not treat
hyperglycemia [12,46]. Therefore, these detrimental effects
possibly could be related to hyperglycemia rather than CSs.
However, even in the trial identifying CSs as a protective
factor for CIP/CIM, the use of CSs was identified as an
independent risk factor for prolonged mechanical ventilation
[44]. Explanations for this remain speculative. As the
diagnosis of CIP/CIM was made (on average) on day 8
whereas prolonged mechanical ventilation was defined from
day 14 onward, CSs may have a time-dependent effect on
the neuromuscular system in critically ill patients charac-
terised by a short-term protective effect and a long-term
deleterious effect. Another explanation could be that precise
identification of the muscular effect of CSs requires the use
of more sophisticated electrophysiological techniques such
as direct muscle stimulation. Further study is needed to
unravel the probable complex effects and their underlying
pathogenetic mechanisms.
Conclusions
Critically ill patients frequently develop CIP/CIM, which
delays weaning, compromises rehabilitation, and is asso-
ciated with increased hospital and ICU stays and increased
mortality rates. Until recently, no therapeutic measures had
been proven to affect its incidence, and apart from supportive
treatment, the only preventive measure was aimed at
controlling the most important risk factor, MOF, as best as
possible. Recently, two trials in a single centre reported that
intensive insulin therapy significantly reduced the
electrophysiological incidence of CIP/CIM and the need for
prolonged mechanical ventilation in patients in the ICU for at
least 1 week. This beneficial effect was present in a surgical
as well as a medical population. However, concerns about
safety and risk for hypoglycemia and limitations of diagnostic
methods used in these trials have been raised, and these
results have not yet been confirmed in a larger population.
Concerning the neuromuscular effects of CSs, the evidence
remains conflicting. Further research should address these
questions and investigate the pathophysiological mecha-
nisms underlying this important clinical problem.
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